The present study not only identified the possible mechanisms underlying TKI resistance but also indicates that players in the FOXM1–CD44 network may become promising therapeutic targets to reverse TKI resistance in HCC. The gene discussed is FOXM1; the disease is hepatocellular carcinoma.